
The next generation of CAR-T cell therapies
Drug Discovery World Editor Reece Armstrong speaks to Dr Jan Davidson-Moncada, Chief Medical Officer at Imviva Biotech about … Read More

Drug Discovery World Editor Reece Armstrong speaks to Dr Jan Davidson-Moncada, Chief Medical Officer at Imviva Biotech about … Read More

Biotech company Laigo Bio has completed the second close of its seed financing round with an additional $5.5 million bringing the total investment to $17 million. Laigo will use the seed financing to accelerate the development of its Surface Removal Targeting Chimeras (SureTACs) oncology programmes towards the clinic. It will… Read More

The European Medicines Agency (EMA) has launched three major new features of PRIME, the Agency’s scheme to enhance support for the development of medicines targeting an unmet medical need. After the completion of a two-year pilot, the EMA has integrated these additional tools to support continued scientific… Read More

The new issue of DDW is now on its way to subscribers and available to read online. The Spring issue explores the next phase of obesity medications and asks how US tariffs are impacting global pharma. It also looks at how India is… Read More

Rare disease therapies could generate over $400 billion in global sales by 2032, a new report reveals. Evaluate’s ‘2026 Orphan Drug Report’ predicts the sales of orphan drugs will continue to rise steadily, despite policy changes and pricing turmoil. According to the forecast, orphan drugs will account for… Read More

Michael Eyres, Lead Scientist at the Medicines Discovery Catapult (MDC), explores how spatial epigenetics can accelerate biomarker drug discovery. Epigenetics, once seen… Read More

A new eBook is now available to download from Bio-Techne entitled ‘Advances in the analysis of next-generation biotherapeutics’. Discover how to accelerate ADC development with clearer, faster characterisation of charge heterogeneity and size/purity. This eBook explains when to apply advanced icIEF and CE-SDS methods for ADCs and other novel biotherapeutics… Read More

Discover how to accelerate ADC development with clearer, faster characterisation of charge heterogeneity and size/purity. This eBook explains when to apply advanced icIEF and CE-SDS methods for ADCs and other novel biotherapeutics to accelerate development timelines. Learn: icIEF vs IEX for ADC charge profiles Protecting unstable ADCs with on-board mixing… Read More

Early tox material can offer valuable clarity as programs progress toward IND. Lonza’s latest white paper introduces a new offering that helps drug developers shorten timelines and generate tox material in as little as 2.5 months. Inside, you will find insights on: Strategies from this new approach that… Read More

An independent company is to be established and led by BioNTech co-founders Professor Ugur Sahin and Professor Özlem Türeci to “advance next-generation mRNA innovations”. BioNTech has announced plans to contribute related rights and mRNA technologies to the new company to support the prioritised development of mRNA innovations… Read More

Mary Brunkow PhD is Senior Program Manager at the Institute for Systems Biology in Seattle in the US. She was one of three co-winners of the 2025 Nobel Prize in Physiology or Medicine for the discovery of regulatory T cells (Tregs). She shares her career highlights and some word of wisdom with Diana Turner. DT: What… Read More

DDW Editor Reece Armstrong speaks to Ali Pashazadeh, CEO of capital market company Treehill Partners, about how his experience of this year’s JPM reflects how the industry will move forward in 2026. The beginning of a new year in drug discovery and development is always marked with the arrival of the JP Morgan Healthcare… Read More

For over a decade, LSX Europe has brought together the leaders shaping the future of life sciences – and on 25-26th March 2026, the organisers are taking the Congress to Lisbon for the first time. The event aims to unite the founders and CEOs of… Read More

DDW Editor Reece Armstrong speaks to Rick Pauls, CEO of DiaMedica, about the company’s efforts in i… Read More

Asahi Kasei Pharma has announced a global license agreement with Alchemedicine to strengthen its drug discovery pipeline. The agreement means Asahi Kasei Pharma can research, develop, manufacture, and commercialise Alchemedicine’s novel lead compounds, which are currently at the preclinical stage. The compounds were identified using Alchemedicine’s drug discovery platform, HiSAP1 and are expected to… Read More

Drug Discovery World speaks to companies at the cutting edge of innovation in blood cancer therapeutics. The prognosis for patients with blood cancers has improved dramatically since the turn of the century. Thanks to an ever-growing array of treatments becoming available, there has been significant… Read More